Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan Bielack, Mark L. Bernstein, Gordana Jovic et al.|Journal of Clinical Oncology|2015Cited by 419
Cancer survivorship practices, services, and delivery: a report from the Children’s Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committeesDebra Eshelman‐Kent, David R. Freyer, Karen E. Kinahan et al.|Journal of Cancer Survivorship|2011Cited by 114